Olema Pharmaceuticals (OLMA) Financials

Olema Pharmaceuticals logo
$7.22 -0.14 (-1.90%)
Closing price 04:00 PM Eastern
Extended Trading
$7.22 +0.00 (+0.07%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Olema Pharmaceuticals

Annual Income Statements for Olema Pharmaceuticals

This table shows Olema Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-4.32 -24 -71 -105 -97 -129 -162
Consolidated Net Income / (Loss)
-4.32 -22 -71 -105 -97 -129 -162
Net Income / (Loss) Continuing Operations
-4.32 -22 -71 -105 -97 -129 -162
Total Pre-Tax Income
-4.32 -22 -71 -105 -97 -129 -162
Total Operating Income
-4.32 -22 -71 -107 -105 -142 -179
Total Gross Profit
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
4.32 22 71 107 105 142 179
Selling, General & Admin Expense
0.40 7.82 20 25 19 18 21
Research & Development Expense
3.92 14 51 82 86 125 158
Total Other Income / (Expense), net
0.01 -0.59 0.40 2.20 8.31 13 16
Interest & Investment Income
0.01 0.06 0.44 2.23 8.33 13 16
Other Income / (Expense), net
0.00 0.00 -0.05 -0.03 -0.02 0.10 0.02
Basic Earnings per Share
($1.66) ($3.42) ($1.80) ($2.62) ($2.14) ($2.20) ($1.87)
Weighted Average Basic Shares Outstanding
2.59M 7.02M 39.52M 40.00M 45.25M 58.74M 87.01M
Diluted Earnings per Share
($1.66) ($3.42) ($1.80) ($2.62) ($2.14) ($2.20) ($1.87)
Weighted Average Diluted Shares Outstanding
2.59M 7.02M 39.52M 40.00M 45.25M 58.74M 87.01M
Weighted Average Basic & Diluted Shares Outstanding
- - 40.35M 40.63M 55.91M 68.33M 87.16M

Quarterly Income Statements for Olema Pharmaceuticals

This table shows Olema Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-31 -30 -35 -34 -30 -44 -42 -46 -53 -63 -74
Consolidated Net Income / (Loss)
-31 -30 -35 -34 -30 -44 -42 -46 -53 -63 -74
Net Income / (Loss) Continuing Operations
-31 -30 -35 -34 -30 -44 -42 -46 -53 -63 -74
Total Pre-Tax Income
-31 -30 -35 -34 -30 -44 -42 -46 -53 -63 -74
Total Operating Income
-34 -34 -38 -37 -35 -48 -46 -50 -58 -67 -78
Total Gross Profit
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
34 34 38 37 35 48 46 50 58 67 78
Selling, General & Admin Expense
4.46 4.42 4.40 4.47 4.25 3.96 5.93 6.86 8.75 9.39 9.93
Research & Development Expense
30 29 33 32 31 44 40 43 49 58 68
Total Other Income / (Expense), net
3.37 3.15 3.07 3.20 4.48 4.08 3.66 4.02 4.90 3.98 3.93
Interest & Investment Income
3.35 3.11 2.93 3.29 4.52 4.04 3.65 4.01 4.78 4.51 4.05
Other Income / (Expense), net
0.02 0.04 0.14 -0.09 -0.04 0.04 0.01 0.01 0.12 -0.53 -0.13
Basic Earnings per Share
($0.56) ($0.54) ($0.60) ($0.50) ($0.36) ($0.51) ($0.49) ($0.51) ($0.52) ($0.61) ($0.73)
Weighted Average Basic Shares Outstanding
55.57M 56.28M 57.26M 58.74M 85.43M 85.50M 85.73M 87.01M 102.80M 104.45M 101.09M
Diluted Earnings per Share
($0.56) ($0.54) ($0.60) ($0.50) ($0.36) ($0.51) ($0.49) ($0.51) ($0.52) ($0.61) ($0.73)
Weighted Average Diluted Shares Outstanding
55.57M 56.28M 57.26M 58.74M 85.43M 85.50M 85.73M 87.01M 102.80M 104.45M 101.09M
Weighted Average Basic & Diluted Shares Outstanding
55.93M 57.27M 57.30M 68.33M 68.42M 85.73M 85.75M 87.16M 87.35M 87.50M 87.61M

Annual Cash Flow Statements for Olema Pharmaceuticals

This table details how cash moves in and out of Olema Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
338 -325 9.89 45 71 -91
Net Cash From Operating Activities
-20 -51 -82 -84 -104 -147
Net Cash From Continuing Operating Activities
-20 -51 -82 -84 -104 -147
Net Income / (Loss) Continuing Operations
-22 -71 -105 -97 -129 -162
Consolidated Net Income / (Loss)
-22 -71 -105 -97 -129 -162
Depreciation Expense
0.01 0.16 0.36 0.38 0.39 0.49
Amortization Expense
0.00 0.28 0.00 0.00 -8.18 -6.29
Non-Cash Adjustments To Reconcile Net Income
3.75 17 19 13 24 19
Changes in Operating Assets and Liabilities, net
-1.51 2.83 3.02 -0.59 9.16 2.78
Net Cash From Investing Activities
-0.06 -275 91 -4.85 -94 -156
Net Cash From Continuing Investing Activities
-0.06 -275 91 -4.85 -94 -156
Purchase of Property, Plant & Equipment
-0.06 -1.58 -0.36 0.00 -0.16 0.00
Purchase of Investments
0.00 -487 -214 -256 -395 -501
Sale and/or Maturity of Investments
0.00 213 306 251 302 345
Net Cash From Financing Activities
358 1.39 0.48 133 269 211
Net Cash From Continuing Financing Activities
358 1.39 0.48 133 269 211
Issuance of Debt
3.00 - - - 0.00 208
Issuance of Common Equity
221 0.72 0.33 131 267 -5.48
Other Financing Activities, net
0.73 0.67 0.15 2.63 1.67 8.39

Quarterly Cash Flow Statements for Olema Pharmaceuticals

This table details how cash moves in and out of Olema Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-35 -17 19 104 -89 1.83 -17 13 4.25 -3.95 -1.08
Net Cash From Operating Activities
-23 -28 -27 -26 -44 -30 -35 -38 -46 -46 -47
Net Cash From Continuing Operating Activities
-23 -28 -27 -26 -44 -30 -35 -38 -46 -46 -47
Net Income / (Loss) Continuing Operations
-31 -30 -35 -34 -30 -44 -42 -46 -53 -63 -74
Consolidated Net Income / (Loss)
-31 -30 -35 -34 -30 -44 -42 -46 -53 -63 -74
Depreciation Expense
0.09 0.09 0.10 0.12 0.13 0.13 0.04 0.19 0.12 0.10 0.09
Non-Cash Adjustments To Reconcile Net Income
2.58 4.08 3.91 4.99 2.26 2.96 2.92 11 8.86 12 11
Changes in Operating Assets and Liabilities, net
4.80 -1.35 3.53 2.18 -16 11 4.73 3.21 -1.88 5.53 15
Net Cash From Investing Activities
-20 -4.88 46 -114 -45 34 17 -162 4.53 41 46
Net Cash From Continuing Investing Activities
-20 -4.88 46 -114 -45 34 17 -162 4.53 41 46
Purchase of Property, Plant & Equipment
-0.15 -0.01 - - - - - - - - -0.90
Purchase of Investments
-76 -82 -47 -189 -143 -33 -72 -253 -70 -48 -51
Sale and/or Maturity of Investments
56 77 93 75 98 67 89 91 74 89 97
Net Cash From Financing Activities
8.82 16 0.09 244 0.22 -2.52 0.04 214 46 1.11 0.43
Net Cash From Continuing Financing Activities
8.82 16 0.09 244 0.22 -2.52 0.04 214 46 1.11 0.43
Other Financing Activities, net
0.92 0.07 0.09 0.59 0.24 0.23 -6.47 14 3.79 0.46 0.43

Annual Balance Sheets for Olema Pharmaceuticals

This table presents Olema Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
343 296 216 277 451 533
Total Current Assets
342 291 209 267 438 515
Cash & Equivalents
339 14 24 69 139 48
Short-Term Investments
0.00 273 181 193 295 457
Prepaid Expenses
3.59 3.44 4.48 4.71 4.39 10
Plant, Property, & Equipment, net
0.08 1.47 0.00 0.00 0.00 0.00
Total Noncurrent Assets
0.51 3.79 6.75 10 13 18
Other Noncurrent Operating Assets
0.51 3.79 6.75 10 13 18
Total Liabilities & Shareholders' Equity
343 296 216 277 451 533
Total Liabilities
4.59 11 18 23 42 55
Total Current Liabilities
4.59 9.02 17 22 42 52
Accounts Payable
0.72 0.02 0.37 2.70 4.46 9.25
Other Current Liabilities
3.87 9.00 16 19 37 43
Total Noncurrent Liabilities
0.00 2.36 1.55 1.43 0.26 3.07
Long-Term Debt
- - - - 0.00 3.00
Other Noncurrent Operating Liabilities
- 2.36 1.55 1.43 0.26 0.07
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
338 285 198 254 409 479
Total Preferred & Common Equity
338 285 198 254 409 479
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
338 285 198 254 409 479
Common Stock
371 389 408 559 844 1,075
Retained Earnings
-33 -104 -209 -306 -435 -598
Accumulated Other Comprehensive Income / (Loss)
0.00 -0.15 -1.81 0.35 0.14 0.62

Quarterly Balance Sheets for Olema Pharmaceuticals

This table presents Olema Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
178 293 264 255 230 410 382 352 531 487 441
Total Current Assets
172 282 252 242 218 397 368 334 513 470 423
Cash & Equivalents
35 117 34 17 36 51 52 35 53 49 48
Short-Term Investments
132 159 215 222 179 342 309 294 453 412 366
Prepaid Expenses
4.07 5.11 3.11 3.08 3.23 3.96 5.81 5.37 7.88 8.81 9.65
Plant, Property, & Equipment, net
1.27 1.06 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets
4.84 9.74 12 12 12 13 14 18 17 17 18
Other Noncurrent Operating Assets
4.84 9.74 12 12 12 13 14 18 17 17 18
Total Liabilities & Shareholders' Equity
178 293 264 255 230 410 382 352 531 487 441
Total Liabilities
16 18 27 27 31 26 37 45 50 56 72
Total Current Liabilities
15 16 26 27 31 26 33 42 47 53 69
Accounts Payable
1.63 2.21 7.66 4.35 2.69 0.15 0.93 3.47 3.72 1.67 1.21
Other Current Liabilities
0.80 0.92 19 22 28 26 32 38 43 51 68
Total Noncurrent Liabilities
1.21 1.70 1.15 0.86 0.56 0.12 3.60 3.31 3.00 3.00 3.00
Long-Term Debt
- - - - - - 3.00 3.00 3.00 3.00 3.00
Other Noncurrent Operating Liabilities
1.21 1.70 1.15 0.86 0.56 0.12 0.60 0.31 0.00 0.00 0.00
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
162 275 236 227 199 383 345 307 480 431 369
Total Preferred & Common Equity
162 275 236 227 199 383 345 307 480 431 369
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
162 275 236 227 199 383 345 307 480 431 369
Common Stock
419 554 573 594 600 849 854 858 1,132 1,145 1,158
Retained Earnings
-257 -279 -337 -367 -402 -465 -509 -551 -651 -714 -787
Accumulated Other Comprehensive Income / (Loss)
-0.52 -0.24 -0.01 -0.12 0.46 0.42 0.31 0.53 -0.46 -0.95 -1.59

Annual Metrics And Ratios for Olema Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Olema Pharmaceuticals' official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
0.00 0.00 40,287,641.00 40,455,427.00 54,769,800.00 - 85,754,086.00
DEI Adjusted Shares Outstanding
0.00 0.00 40,287,641.00 40,455,427.00 54,769,800.00 - 85,754,086.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 0.00 -1.76 -2.59 -1.76 - -1.89
Growth Metrics
- - - - - - -
Profitability Metrics
- - - - - - -
Net Operating Profit after Tax (NOPAT)
-3.03 -15 -50 -75 -73 -100 -125
Return On Investment Capital (ROIC_SIMPLE)
- - - - -28.94% -24.35% -25.98%
Earnings before Interest and Taxes (EBIT)
-4.32 -22 -72 -107 -105 -142 -179
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-4.32 -22 -71 -107 -105 -142 -184
Valuation Ratios
- - - - - - -
Leverage & Solvency
- - - - - - -
Liquidity Ratios
- - - - - - -
Cash Flow Metrics
- - - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -15 -48 -71 -72 -82 -126
Efficiency Ratios
- - - - - - -
Capital & Investment Metrics
- - - - - - -
Invested Capital
0.00 -0.41 -2.68 -6.88 -7.91 -25 -24
Increase / (Decrease) in Invested Capital
0.00 -0.41 -2.27 -4.19 -1.04 -17 1.24
Book Value per Share
$0.00 $48.16 $7.06 $4.88 $4.64 $7.14 $5.58
Tangible Book Value per Share
$0.00 $48.16 $7.06 $4.88 $4.64 $7.14 $5.58
Total Capital
0.00 338 285 198 254 409 482
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 3.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 3.00
Net Debt
0.00 -339 -287 -204 -262 -434 -502
Capital Expenditures (CapEx)
0.00 0.06 1.58 0.36 -0.01 0.16 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
0.00 -1.00 -5.58 -12 -17 -37 -42
Debt-free Net Working Capital (DFNWC)
0.00 338 282 192 245 397 464
Net Working Capital (NWC)
0.00 338 282 192 245 397 464
Net Nonoperating Expense (NNE)
1.29 7.05 21 30 23 30 37
Net Nonoperating Obligations (NNO)
0.00 -339 -287 -204 -262 -434 -502
Total Depreciation and Amortization (D&A)
0.00 0.01 0.44 0.36 0.38 0.39 -5.80
Earnings Adjustments
- - - - - - -
Adjusted Basic Earnings per Share
$0.00 $0.00 ($1.80) ($2.62) ($2.14) ($2.20) ($1.87)
Adjusted Weighted Average Basic Shares Outstanding
0.00 0.00 39.52M 40.00M 45.25M 58.74M 87.01M
Adjusted Diluted Earnings per Share
$0.00 $0.00 ($1.80) ($2.62) ($2.14) ($2.20) ($1.87)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 0.00 39.52M 40.00M 45.25M 58.74M 87.01M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 0.00 40.35M 40.63M 55.91M 68.33M 87.16M
Normalized Net Operating Profit after Tax (NOPAT)
-3.03 -15 -50 -75 -73 -100 -125
Debt Service Ratios
- - - - - - -
Payout Ratios
- - - - - - -

Quarterly Metrics And Ratios for Olema Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Olema Pharmaceuticals' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
55,914,741.00 55,933,827.00 57,266,358.00 - 68,333,065.00 68,421,277.00 85,728,492.00 85,754,086.00 87,156,961.00 87,347,471.00 87,497,607.00
DEI Adjusted Shares Outstanding
55,914,741.00 55,933,827.00 57,266,358.00 - 68,333,065.00 68,421,277.00 85,728,492.00 85,754,086.00 87,156,961.00 87,347,471.00 87,497,607.00
DEI Earnings Per Adjusted Shares Outstanding
-0.55 -0.54 -0.60 - -0.44 -0.64 -0.49 -0.54 -0.61 -0.72 -0.84
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
EBITDA Growth
-16.08% -55.00% -60.25% -21.53% -1.61% -42.81% -22.56% - -66.01% -41.75% -69.26%
EBIT Growth
-15.99% -54.72% -60.04% -21.56% -1.72% -42.81% -22.36% - -65.74% -41.57% -69.31%
NOPAT Growth
-16.00% -55.22% -61.17% -20.88% -1.56% -42.75% -21.95% - -66.28% -40.35% -68.98%
Net Income Growth
-9.49% -51.19% -60.71% -25.38% 1.88% -44.11% -22.17% - -74.70% -44.35% -74.34%
EPS Growth
20.00% -10.20% -25.00% -6.38% 35.71% 5.56% 18.33% - -44.44% -19.61% -48.98%
Operating Cash Flow Growth
-15.23% -24.59% -18.78% -42.26% -87.18% -8.45% -27.80% - -4.57% -53.59% -36.45%
Free Cash Flow Firm Growth
-78.58% -27.06% 37.10% 57.90% -24.41% -82.67% -140.77% - -0.58% -4.49% -4.45%
Invested Capital Growth
-15.30% -103.74% -797.11% -217.52% 26.89% -14.54% -16.53% - -136.29% -101.11% -127.01%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
-13.23% 2.45% -11.95% 1.72% 5.33% -37.11% 3.93% - -15.76% -17.07% -14.72%
EBIT Q/Q Growth
-13.19% 2.42% -11.92% 1.66% 5.28% -36.99% 4.10% - -15.57% -17.01% -14.69%
NOPAT Q/Q Growth
-12.90% 2.36% -12.20% 2.27% 5.15% -37.25% 4.15% - -15.78% -15.85% -15.40%
Net Income Q/Q Growth
-15.68% 1.90% -13.74% 2.86% 9.47% -44.08% 3.58% - -15.26% -19.05% -16.45%
EPS Q/Q Growth
-19.15% 3.57% -11.11% 16.67% 28.00% -41.67% 3.92% - -1.96% -17.31% -19.67%
Operating Cash Flow Q/Q Growth
-27.17% -17.28% 1.96% 2.71% -67.32% 32.05% -15.54% - -19.99% 0.20% -2.65%
Free Cash Flow Firm Q/Q Growth
-10.38% 22.21% 29.56% 30.39% -226.18% -14.21% 7.16% - 22.94% -18.66% 7.20%
Invested Capital Q/Q Growth
-60.00% 5.67% -32.75% -58.48% 63.16% -47.78% -35.06% - 8.41% -25.78% -52.45%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00% 100.00% 100.00%
Interest Burden Percent
90.23% 90.72% 92.19% 91.06% 87.04% 91.55% 92.05% - 91.75% 93.34% 94.78%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Equity (ROE)
-48.31% -56.40% -51.76% -39.07% -41.59% -49.72% -59.22% - -42.86% -52.74% -69.77%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-48.31% -56.40% -51.76% -39.07% -41.59% -49.72% -59.22% - -42.86% -52.74% -69.77%
Return on Equity Simple (ROE_SIMPLE)
-42.04% 0.00% 0.00% 0.00% -33.61% 0.00% 0.00% - 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-24 -23 -26 -26 -24 -34 -32 -35 -41 -47 -54
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-3.19% -3.40% -3.34% -2.25% -1.86% -3.44% -3.74% - -2.79% -3.96% -5.25%
Return On Investment Capital (ROIC_SIMPLE)
-10.17% -10.33% -13.24% -6.29% -6.37% -9.62% -10.34% -7.28% -8.40% -10.85% -14.59%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-34 -33 -37 -37 -35 -48 -46 -50 -58 -68 -78
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-34 -33 -37 -37 -35 -48 -46 -50 -58 -68 -78
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
2.68 2.66 3.44 0.82 0.67 0.84 2.73 - 2.70 2.54 2.05
Price to Tangible Book Value (P/TBV)
2.68 2.66 3.44 0.82 0.67 0.84 2.73 - 2.70 2.54 2.05
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.01 0.01 - 0.01 0.01 0.01
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.01 0.01 - 0.01 0.01 0.01
Financial Leverage
-1.06 -1.05 -1.04 -1.05 -1.04 -1.04 -1.07 - -1.04 -1.05 -1.09
Leverage Ratio
1.12 1.11 1.10 1.10 1.09 1.11 1.15 - 1.09 1.12 1.17
Compound Leverage Factor
1.01 1.01 1.02 1.00 0.95 1.02 1.06 - 1.00 1.05 1.11
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.86% 0.97% - 0.62% 0.69% 0.81%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.86% 0.97% - 0.62% 0.69% 0.81%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 99.14% 99.03% - 99.38% 99.31% 99.19%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 -0.02 -0.02 - -0.01 -0.01 -0.01
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 2.29 1.98 - 2.50 2.07 1.62
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 -0.02 -0.02 - -0.01 -0.01 -0.01
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 -0.03 -0.03 - -0.02 -0.02 -0.02
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 3.26 2.82 - 3.56 2.96 2.32
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 -0.03 -0.03 - -0.02 -0.02 -0.02
Altman Z-Score
12.68 11.82 11.12 4.21 5.10 3.53 9.58 - 14.52 10.22 4.16
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
9.61 9.13 7.10 10.50 15.22 11.09 8.03 - 10.88 8.86 6.12
Quick Ratio
9.49 9.01 7.00 10.40 15.07 10.91 7.90 - 10.71 8.70 5.98
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-22 -17 -12 -8.53 -28 -32 -29 -36 -28 -33 -31
Operating Cash Flow to CapEx
-15,356.86% -459,250.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% -5,234.67%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-13 -12 -16 -25 -9.26 -14 -18 -24 -22 -28 -42
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
-1.68 -6.08 -14 -17 3.40 -1.74 -2.62 1.24 -13 -14 -23
Enterprise Value (EV)
384 366 469 -100 -136 -67 513 - 797 635 345
Market Capitalization
633 605 684 334 257 291 839 - 1,300 1,093 756
Book Value per Share
$4.23 $4.06 $3.47 $7.14 $5.61 $5.05 $3.59 $5.58 $5.51 $4.93 $4.22
Tangible Book Value per Share
$4.23 $4.06 $3.47 $7.14 $5.61 $5.05 $3.59 $5.58 $5.51 $4.93 $4.22
Total Capital
236 227 199 409 383 348 310 482 483 434 372
Total Debt
0.00 0.00 0.00 0.00 0.00 3.00 3.00 3.00 3.00 3.00 3.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 3.00 3.00 3.00 3.00 3.00 3.00
Net Debt
-249 -239 -215 -434 -393 -359 -326 -502 -502 -458 -411
Capital Expenditures (CapEx)
0.15 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.90
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-23 -23 -27 -37 -22 -27 -36 -42 -39 -44 -60
Debt-free Net Working Capital (DFNWC)
226 216 187 397 371 335 293 464 466 417 354
Net Working Capital (NWC)
226 216 187 397 371 335 293 464 466 417 354
Net Nonoperating Expense (NNE)
6.93 6.91 8.22 7.83 5.98 10 10 11 12 16 19
Net Nonoperating Obligations (NNO)
-249 -239 -215 -434 -393 -359 -326 -502 -502 -458 -411
Total Depreciation and Amortization (D&A)
0.09 0.09 0.10 0.12 0.13 0.13 0.04 0.19 0.12 0.10 0.09
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.56) ($0.54) ($0.60) ($0.50) ($0.36) ($0.51) ($0.49) ($0.51) ($0.52) ($0.61) ($0.73)
Adjusted Weighted Average Basic Shares Outstanding
55.57M 56.28M 57.26M 58.74M 85.43M 85.50M 85.73M 87.01M 102.80M 104.45M 101.09M
Adjusted Diluted Earnings per Share
($0.56) ($0.54) ($0.60) ($0.50) ($0.36) ($0.51) ($0.49) ($0.51) ($0.52) ($0.61) ($0.73)
Adjusted Weighted Average Diluted Shares Outstanding
55.57M 56.28M 57.26M 58.74M 85.43M 85.50M 85.73M 87.01M 102.80M 104.45M 101.09M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
55.93M 57.27M 57.30M 68.33M 68.42M 85.73M 85.75M 87.16M 87.35M 87.50M 87.61M
Normalized Net Operating Profit after Tax (NOPAT)
-24 -23 -26 -26 -24 -34 -32 -35 -41 -47 -54
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Olema Pharmaceuticals remains a development-stage biotechnology company with no reported revenue. Its financial results continue to be driven by research and development spending, investment income and external financing rather than product sales.

Liquidity remains the company’s primary financial strength. As of June 30, 2026, Olema held $48.6 million in cash and $412.5 million in short-term investments, for total cash and liquid investments of approximately $461.1 million. This was down from approximately $505.3 million at the end of the first quarter, but substantially above the roughly $361.9 million held at the end of the second quarter of 2025. Total liabilities were only $56.0 million, including $3.0 million of long-term debt, giving the company a strong net cash position.

However, Olema’s cash burn is increasing as its clinical programs advance. Second-quarter operating cash outflow was $45.9 million, roughly unchanged from $46.0 million in the first quarter but significantly higher than $29.9 million in the second quarter of 2025 and $27.6 million in the second quarter of 2024. At the latest quarterly burn rate, its cash and short-term investments provide a theoretical runway of about 10 quarters, before considering changes in spending, investment income, financing or clinical costs.

Operating losses are also widening. Second-quarter 2026 research and development expense rose to $57.8 million from $49.2 million in the first quarter and $43.9 million in the second quarter of 2025. Total operating expenses reached $67.2 million, producing a net loss of $63.2 million, or $0.61 per share. This compares with a $53.1 million loss in the first quarter and a $43.8 million loss in the year-ago quarter.

  • Substantial liquidity: Cash and short-term investments totaled approximately $461.1 million at June 30, 2026, providing funding for ongoing research and clinical development.
  • Low leverage: Total liabilities of $56.0 million were modest relative to $486.6 million of assets, while long-term debt remained at only $3.0 million.
  • Investment income supports the cash position: Interest and investment income contributed $4.5 million in the second quarter, partially offsetting operating losses.
  • Financing dependence eased in the latest quarter: Olema raised only $652,000 through common equity issuance in Q2 2026, compared with $41.9 million in Q1 2026 and $205.4 million of debt financing in Q4 2025.
  • Investment portfolio activity is significant: The company purchased $48.2 million and sold or received maturities of $89.3 million of investments during Q2 2026. The resulting $40.8 million investing cash inflow reflects portfolio management rather than operating profitability.
  • Equity remains positive but is declining: Total equity was $430.6 million at June 30, 2026, down from $480.5 million at March 31, 2026, primarily reflecting continued quarterly losses.
  • No revenue generation yet: Olema reported zero revenue and zero gross profit in the latest quarter and throughout the periods provided, leaving the company dependent on future clinical and commercial success.
  • Operating losses are accelerating: Q2 2026 operating expenses of $67.2 million were well above $47.9 million in Q2 2024 and $21.6 million in Q2 2023, with research and development accounting for most of the increase.
  • Higher cash burn reduces runway: Quarterly operating cash outflow of $45.9 million in Q2 2026 was materially higher than the comparable periods in 2024 and 2025, increasing the likelihood of future capital raises if spending remains elevated.
  • Shareholder dilution is a growing concern: Weighted-average basic shares rose to 104.5 million in Q2 2026 from 85.5 million in Q2 2025 and 55.6 million in Q1 2024, reducing each existing shareholder’s ownership percentage.

Overall, Olema’s balance sheet is currently well funded and lightly leveraged, which supports continued investment in its pipeline. The primary risks are the absence of revenue, rising research costs, persistent losses and increasing share dilution. Investors should focus on clinical progress and whether the company can eventually convert its substantial cash resources into a commercially successful product before its runway becomes constrained.

11/18/26 12:50 AM ETAI Generated. May Contain Errors.

Olema Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Olema Pharmaceuticals' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Olema Pharmaceuticals' net income appears to be on a downward trend, with a most recent value of -$162.45 million in 2025, falling from -$4.32 million in 2019. The previous period was -$129.47 million in 2024. See where experts think Olema Pharmaceuticals is headed by visiting Olema Pharmaceuticals' forecast page.

Olema Pharmaceuticals' total operating income in 2025 was -$178.70 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $178.70 million

Over the last 6 years, Olema Pharmaceuticals' total revenue changed from $0.00 in 2019 to $0.00 in 2025, a change of 0.0%.

In the past 13 quarters, Olema Pharmaceuticals' cash and equivalents has ranged from $16.89 million in Q2 2024 to $117.41 million in Q3 2023, and is currently $47.52 million as of their latest financial filing in Q3 2026.

Olema Pharmaceuticals had total debt of $3 million at the end of 2025, compared with none in 2024, and none in 2019.

Over the last 6 years, Olema Pharmaceuticals' book value per share changed from 0.00 in 2019 to 5.58 in 2025, a change of 558.1%.



Financial statements for NASDAQ:OLMA last updated on 11/10/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners